Unknown

Dataset Information

0

Inhibition of necroptosis attenuates lung injury and improves survival in neonatal sepsis.


ABSTRACT: BACKGROUND:Neonatal sepsis represents a unique therapeutic challenge owing to an immature immune system. Necroptosis is a form of programmed cell death that has been identified as an important mechanism of inflammation-induced cell death. Receptor-interacting protein kinase 1 plays a key role in mediating this process. We hypothesized that pharmacologic blockade of receptor-interacting protein kinase 1 activity would be protective in neonatal sepsis. METHODS:Sepsis was induced in C57BL/6 mouse pups (5-7 days old) by intraperitoneal injection of adult cecal slurry. At 1 hour after cecal slurry injection, the receptor-interacting protein kinase 1 inhibitor necrostatin-1 (10 µg/g body weight) or vehicle (5% dimethyl sulfoxide in phosphate buffered saline) was administered via retro-orbital injection. At 20 hours after cecal slurry injection, blood and lung tissues were collected for various analyses. RESULTS:At 20 hours after sepsis induction, vehicle-treated pups showed a marked increase in serum levels of interleukin 6, interleukin 1-beta, and interleukin 18 compared to sham. With necrostatin-1 treatment, serum levels of interleukin 6, interleukin 1-beta, and interleukin 18 were decreased by 77%, 81%, and 63%, respectively, compared to vehicle. In the lungs, sepsis induction resulted in a 232-, 10-, and 2.8-fold increase in interleukin 6, interleukin 1-beta, and interleukin 18 mRNA levels compared to sham, while necrostatin-1 treatment decreased these levels to 40-, 4-, and 0.8-fold, respectively. Expressions of the neutrophil chemokines keratinocyte chemoattractant and macrophage-inflammatory-protein-2 were also increased in the lungs in sepsis, while necrostatin-1 treatment decreased these levels by 81% and 61%, respectively, compared to vehicle. In addition, necrostatin-1 treatment significantly improved the lung histologic injury score and decreased lung apoptosis in septic pups. Finally, treatment with necrostatin-1 increased the 7-day survival rate from 0% in the vehicle-treated septic pups to 29% (P?=?.11). CONCLUSION:Inhibition of receptor-interacting protein kinase 1 by necrostatin-1 decreases systemic and pulmonary inflammation, decreases lung injury, and increases survival in neonatal mice with sepsis. Targeting the necroptosis pathway might represent a new therapeutic strategy for neonatal sepsis.

SUBMITTER: Bolognese AC 

PROVIDER: S-EPMC6204110 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of necroptosis attenuates lung injury and improves survival in neonatal sepsis.

Bolognese Alexandra C AC   Yang Weng-Lang WL   Hansen Laura W LW   Denning Naomi-Liza NL   Nicastro Jeffrey M JM   Coppa Gene F GF   Wang Ping P  

Surgery 20180427


<h4>Background</h4>Neonatal sepsis represents a unique therapeutic challenge owing to an immature immune system. Necroptosis is a form of programmed cell death that has been identified as an important mechanism of inflammation-induced cell death. Receptor-interacting protein kinase 1 plays a key role in mediating this process. We hypothesized that pharmacologic blockade of receptor-interacting protein kinase 1 activity would be protective in neonatal sepsis.<h4>Methods</h4>Sepsis was induced in  ...[more]

Similar Datasets

| S-EPMC6333887 | biostudies-literature
| S-EPMC8892593 | biostudies-literature
| S-EPMC3349366 | biostudies-literature
| S-EPMC4056775 | biostudies-other
| S-EPMC9437591 | biostudies-literature
| S-EPMC7913048 | biostudies-literature
| S-EPMC8312235 | biostudies-literature
| S-EPMC5023024 | biostudies-literature
| S-EPMC3001263 | biostudies-literature
| S-EPMC4792660 | biostudies-literature